SCM
CSCI

Sterneck Capital Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Sterneck Capital Management’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$7K – 109
2021
Q4 		$7K Hold
200
– – ﹤0.01% 108
2021
Q3 		$15K Hold
200
– – 0.01% 102
2021
Q2 		$15K Buy
+200
New +$19K 0.01% 103

Other funds holding CSCI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sterneck Capital Management's CSCI Position: Q1 2022 in Review

Sterneck Capital Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q1 2022, closing a stake of 200 shares — an estimated $7K sold.

Sterneck Capital Management first reported a position in CSCI in Q2 2021 and held it in 3 quarters. The position peaked at $15K in Q3 2021. 23 funds tracked by Wall St. Rank hold CSCI as of Q1 2022.

  • Sterneck Capital Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Sterneck Capital Management sold 200 COSCIENS Biopharma Inc. Common Stock shares in Q1 2022, an estimated $7K.
  • Sterneck Capital Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Sterneck Capital Management's COSCIENS Biopharma Inc. Common Stock position peaked at $15K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q1 2022.

Based on Sterneck Capital Management's 13F filing for Q1 2022, filed 3 May 2022.